BioSpace News Archive

OSI today announced the acquisition of a Varian Truebeam Radiotherapy System.

The change, which also includes a new corporate logo and branding platform, reflects the Company’s continuing vision and development of its regenerative medicine technologies portfolio, and its lead product, ECMH.

To transform the reporting experience of over 75 radiologists, Clinical Radiologists will utilize M*Modal’s speech-driven, quality-focused imaging solutions that enable radiologists to deliver greater and demonstrable value throughout the continuum of care.

The new advancements give clinicians more accessible and mobile-friendly resources and accreditation opportunities that fit into their on-the-go schedules.

BD has amended the Exchange Offers and Consent Solicitations to extend the expiration date of the Exchange Offers and Consent Solicitations from 12:01 a.m., New York City time, on November 28, 2017 to 5:00 p.m., New York City time, on December 14, 2017 which date and time may be modified as described below.

The application is based on results from the Phase 3 CheckMate -214 study.

ITUS is developing a platform called Cchek from which it expects to launch a series of non-invasive, inexpensive diagnostic blood tests for early cancer detection.

This divestment allows Sample6 to focus exclusively on its groundbreaking and highly-regarded CONTROL food safety software.

The funding was provided by Zhongji Holdings LTD/Join Medical Technology, TAMCAP LLC, BrilliMedical International Corp., BioPacific Investors, Western Technology Investment, and FundRx.

Greene joins MedLumics from Seroba Lifesciences, a venture capital firm based in Dublin, where he was a partner.